JAC Advance Access published online on September 1, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg400
© 2003 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brief report
1 Unité des staphylocoques,
Institut Pasteur, 75724 Paris Cedex
* Corresponding author. E-mail: nelsolh{at}pasteur.fr.
Received 31 March 2003
; revised 27 June 2003
; accepted 2 July 2003
According to the French Society of Microbiology, Staphylococcus aureus isolates are suspected to
have decreased susceptibility to glycopeptide(s) when at least one
colony is able to grow from an inoculum of 10 µL
of 2 McFarland bacterial suspension plated on Mueller-Hinton
agar containing 5 mg/L teicoplanin and incubated for 48 h at 35-37°C. We analysed 89 methicillin-resistant S. aureus isolates (MRSA), collected in 2000-2001
from 24 hospitals located in 18 French cities, which were able to
grow on this selective medium. These isolates were distributed into
six groups on the basis of their glycopeptide resistance phenotypes:
(A) glycopeptide susceptible (GSSA, 21 isolates); (B) heterogeneous
teicoplanin intermediately resistant (hetero-TISA, 24 isolates);
(C) heterogeneous and intermediately resistant to both glycopeptides,
teicoplanin and vancomycin (hetero-GISA, six isolates); (D) heterogeneous
vancomycin intermediately resistant/teicoplanin intermediately resistant
(hetero-VISA/TISA, 30 isolates); (E) GISA (four isolates); (F) TISA
(four isolates). Despite the persistent decrease in gentamicin-resistant
MRSA isolates in French hospitals since 1993, their prevalence is
very high in groups D, E and F. Moreover, most of the group C, D
and E isolates exhibiting decreased susceptibility to both glycopeptides
belong to the same major SmaI genotype, which has
been detected in Europe since at least 1989.
Keywords: MRSA, S. aureus, teicoplanin,
vancomycin
Characteristics of French methicillin-resistant Staphylococcus aureus isolates with decreased susceptibility
or resistance to glycopeptides
2 Département des maladies infectieuses,
Institut de veille sanitaire, 94415 Saint-Maurice Cedex
3 Laboratoire de Bactériologie-Virologie-Hygiène,
CHU Rangueil, 31403 Toulouse Cedex 4, France
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Wang, J. F. Hindler, K. W. Ward, and D. A. Bruckner Increased Vancomycin MICs for Staphylococcus aureus Clinical Isolates from a University Hospital during a 5-Year Period J. Clin. Microbiol., November 1, 2006; 44(11): 3883 - 3886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Trueba, E. Garrabe, R. Hadef, R. Fabre, J.-D. Cavallo, K. Tsvetkova, and O. Chesneau High Prevalence of Teicoplanin Resistance among Staphylococcus epidermidis Strains in a 5-Year Retrospective Study. J. Clin. Microbiol., May 1, 2006; 44(5): 1922 - 1923. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Robert, R. Bismuth, and V. Jarlier Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002 J. Antimicrob. Chemother., March 1, 2006; 57(3): 506 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. J. Brown, D. I. Edwards, P. M. Hawkey, D. Morrison, G. L. Ridgway, K. J. Towner, M. W. D. Wren, and on behalf of the Joint Working Party of the Britis Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA) J. Antimicrob. Chemother., December 1, 2005; 56(6): 1000 - 1018. [Abstract] [Full Text] [PDF]
|
|